NCT07100470View on ClinicalTrials.gov

Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET

NANot yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2028

Study Completion Date

March 1, 2029

Conditions
FTDADHealthy Controls
Interventions
DIAGNOSTIC_TEST

Sodium MRI

Sodium MRI is used to detect early metabolic alterations in neurodegenerative diseases

All Listed Sponsors
lead

Centre Hospitalier St Anne

OTHER

NCT07100470 - Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET | Biotech Hunter | Biotech Hunter